Recornea is an Italian healthcare startup that aims to address pathological corneal shape deformations (PCSDs) with their revolutionary GROSSO® corneal implants. These implants are designed to restore the natural shape of corneas, offering a solution for conditions such as keratoconus, corneal thinning post-laser treatments, and deformations following corneal transplants.
Founded in 2015, Recornea has positioned itself as a pioneer in the ophthalmic devices industry. Their innovative product, GROSSO® implants, fills a crucial gap in the market and has the potential to significantly impact the field of ophthalmology.
While specific details about their last investment are currently unavailable, Recornea's groundbreaking technology and potential for disrupting the ophthalmic care landscape make it an intriguing prospect for venture capital firms seeking to invest in innovative healthcare solutions.